Antihypertensive and vasorelaxant effects of aqueous extract of Artemisia campestris L. from Eastern Morocco. by Dib, Ikram et al.
Author’s Accepted Manuscript
Antihypertensive and vasorelaxant effects of
aqueous extract of Artemisia campestris L. from
Eastern Morocco
Ikram Dib, Monique Tits, Luc Angenot, Jean Noel
Wauters, Asmae Assaidi, Hassane Mekhfi,
Mohammed Aziz, Mohammed Bnouham,





To appear in: Journal of Ethnopharmacology
Received date: 25 January 2017
Revised date: 5 May 2017
Accepted date: 30 May 2017
Cite this article as: Ikram Dib, Monique Tits, Luc Angenot, Jean Noel Wauters,
Asmae Assaidi, Hassane Mekhfi, Mohammed Aziz, Mohammed Bnouham,
Abdelkhaleq Legssyer, Michel Frederich and Abderrahim Ziyyat,
Antihypertensive and vasorelaxant effects of aqueous extract of Artemisia
campestris L. from Eastern Morocco, Journal of Ethnopharmacology,
http://dx.doi.org/10.1016/j.jep.2017.05.036
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version of
the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable form.
Please note that during the production process errors may be discovered which




Antihypertensive and vasorelaxant effects of aqueous extract of Artemisia 
campestris L. from Eastern Morocco 
Ikram Diba1, Monique Titsb2, Luc Angenotb, Jean Noel Wautersb3, Asmae Assaidia4, 
Hassane Mekhfia5, Mohammed Aziza, Mohammed Bnouhama, Abdelkhaleq Legssyera, 
Michel Frederichb6, Abderrahim Ziyyata*  
a Laboratoire de Physiologie, Génétique et Ethnopharmacologie URAC-40, Département 
de Biologie, Faculté des Sciences, Université Mohammed Premier, Oujda-Maroc.  
b Laboratoire de Pharmacognosie, Centre Interfacultaire de Recherche sur les 











                                                          
1
 +212 (0)6 78 19 07 50 
2
 +32 (0)43 66 43 34 
3
 +32 (0)43 66 43 35 
4
 +212 (0)6 16 19 74 54 
5
 +212 (0)5 36 50 90 77 (N° tel de laboratoire) 
6





*Correspondence to : Pr Abderrahim ZIYYAT Laboratoire de Physiologie, Génétique et 
Ethnopharmacologie, Département de Biologie, Faculté des Sciences, Université 
Mohamed Premier, Oujda – Maroc. Tel.: +(212) 6 67 08 61 22.  
 
Abstract 
Ethnopharmacological relevance:  
Artemisia campestris L. (Asteraceae) has many traditional uses, among which 
treatment of diabetes and hypertension. 
Aim of the study 
This study was conducted in order to confirm the antihypertensive and hypotensive 
effects of A. campestris L. aqueous extract (AcAE) and to explore the underlying 
mechanism of action of its vasorelaxant effect, besides the acute toxicity. Also, the 
chemical composition of AcAE was investigated.  
Material and methods 
the chemical content of AcAE was determined by using HPLC and NMR techniques. The 
antihypertensive effect was assessed indirectly by tail-cuff method on L-NAME induced 
hypertensive rats, while the hypotensive action was monitored intravenously by 
invasive method on normotensive rats. The vasorelaxant effect and vascular 
mechanism of action were studied in the presence of antagonists and blockers on 
aorta isolated from normotensive rats. On the other side, the acute toxicity was 




The global phytochemical profile of AcAE reveals the presence of several polyphenols 
as main components. A. campestris L. infusion was characterized by mono- and di-
cinnamoyl compounds, with 3,5-dicaffeoylquinic (isochlorogenic A) acid being the main 
compound, followed by 5-caffeoylquinic (chlorogenic) acid. Vicenin-2 (apigenin 6,8-di-
C-glucoside) appeared to be the most abundant compound among flavonoids.The daily 
treatment with AcAE at 150 mg/Kg/day prevented the installation of hypertension on 
L-NAME hypertensive rats, and reduced SBP from 172 mmHg up to 144 mmHg. At the 
dose 40 mg/Kg, AcAE provoked reduction of systolic (SBP), diastolic (DBP) and mean 
arterial pressure (MAP), without affecting the heart rate. Also, AcAE (10-2-2 mg/ml) 
relaxed the precontracted aorta by 95.8 ± 1.3%. The denudation and preincubation of 
aorta with atropine, calmidazolium, L-NAME, hydroxycobalamin, ODQ, 8-RP-Br-PET-
cGMP, thapsigargin and verapamil attenuated the vasorelaxant response, while the 
pre-treatment with 4-AP, TEA, glibenclamide and BaCl2 did not alter this effect. The 
oral administration of AcAE (0-6 g/Kg) reveals no mortality or toxicity. 
Conclusions 
our study proved that AcAE possess an important antihypertensive, hypotensive and 
vasorelaxant effect, which is mediated via calmodulin-NO-cGC-PKG pathway, and via 
inhibition of calcium influx through voltage-operated calcium channels and activation 
of intracellular calcium mobilization into sarcoplasmic reticulum. Therefore, our 







Artemisia campestris L., aqueous extract, phytochemical analysis, antihypertensive, 
hypotensive, vasorelaxant. 
Chemical compounds studied in this article 
Chlorogenic acid (PubChem CID: 1794427); 3,4- Dicaffeoylquinic acid (PubChem CID: 
5281780); 3,5- Dicaffeoylquinic acid (PubChem CID: 6474310); 4,5- Dicaffeoylquinic 





Hypertension is considered as the main current concern of public health due to its high 
prevalence and its related risk factors. In Africa, the global prevalence attained it 
maximum by the year 2000 and was estimated by 30.8%, with 33.3% as prevalence 
average in Northern Africa (Adeloye and Basquill, 2014). In Morocco, the prevalence of 
this disease was about 33.6% (Tazi et al., 2003), while the frequency of hypertension in 
Eastern Morocco was accounted for 31.7% (Ziyyat et al., 2014). Even though, the 
antihypertensive drugs consumption among the Moroccan hypertensive population 
remains very low for their needs (Berrada El Azizi et al., 2012), which lead to the 
utilization of traditional herbal medicine as an alternative to treat high blood pressure. 
According to ethnomedicinal surveys conducted in four regions of Morocco, 67.5% to 
80% of patients use medicinal plants to treat hypertension (Eddouks et al., 2002; Jouad 
et al., 2001; Tahraoui et al., 2007; Ziyyat et al., 1997). Artemisia campestris L. 
(Asteraceae) is an Eastern Morocco medicinal plant (Fakchich and Elachouri, 2014), 
that has been botanically identified and characterized based on its essential oil chemo-
typing (Dib et al., 2017a). This plant is commonly used as antihypertensive (Boudjelal 
et al., 2013) besides to other common uses like antidiabetic (Bnouham et al., 2002; 
Boudjelal et al., 2013) diuretic (Benchelah et al., 2004; Ferchichi et al., 2006), 
emmenagogue (Benchelah et al., 2004; Hammiche and Maiza, 2006; Popović et al., 
2012), against digestive (Djidel et al., 2009; Fakchich and Elachouri, 2014; Hammiche 
and Maiza, 2006; Leporatti and Ghedira, 2009) and cutaneous problems (Benítez et al., 
2010; El Hassani et al., 2013), as febrifuge (Guarino et al., 2008), anthelmintic 
(Hammiche and Maiza, 2006; Popović et al., 2012). The overall of traditional uses and 
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pharmacological studies of this plant were detailed in a review published by our team 
(Dib et al., 2016). 
According to Ben-Nasr et al. (2014a), it has been evidenced that the water extract of A. 
campestris decreased significantly the diastolic pressure and heart rate in both smoker 
and non-smoker men, but the systolic pressure did not significantly change. The same 
author performed experiments on envenomed pregnant and non-pregnant rats with 
hypertensive phase induced by the venom, and proved that the pre-treatment with 
the aqueous decoction of A. campestris leaves exhibited a preventive antihypertensive 
effect, and abolished the venom induced hypertensive shock (Ben Nasr et al., 2014b). 
Recently, we have showed that the essential oil of A. campestris L. exhibited a 
powerful vasorelaxant effect, which was endothelium-independent, and mediated via 
calcium channels (Dib et al 2017b). In this perspective, this study was carried out with 
the objective to confirm the antihypertensive action of A. campestris L. aqueous 
extract (AcAE), on L-NAME-induced hypertensive rats. The effect of AcAE on normal 
blood pressure rats was also explored, and its vasorelaxant effect was studied, with an 
emphasis to the vascular mechanism of action. Finally, the phytochemical composition 
of AcAE was characterized with the aim to give a chemical fingerprinting of this plant 
according to its occurrence in Oriental Morocco. 
2. Material and methods 
2.1. Plant material 
Aerial part of A. campestris L. was collected in 2014 at flowering stage in a desert area 
situated between Tendrara and Figuig (South-Eastern Morocco), called chott Tiggri 
(32°49’48’’ N, 1°39’36’’ w). The plant material was identified by Pr. Atika Mihamou 
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botanist from biology department, and a voucher specimen was deposited in the 
Herbarium of Faculty of Sciences, University Mohamed First (Oujda, Morocco) under 
the reference number (HUMPOM-151). The name of the plant was checked and 
confirmed according the official website www.theplantlist.org.    
2.2. Preparation of aqueous extract  
A quantity of 250g of A. campestris L. aerial part was infused in boiled distilled water 
during 4 hours. Then, the extract (AcAE) was filtered and the pooled extract was 
evaporated to dryness in a rotary evaporator. The yield extract was about 8.37%. The 
extract was stored at -20°C until use. 
2.3. Chemicals and drugs 
The following drugs and solvents were used in this study: (±)-verapamil hydrochloride 
(Sigma Aldrich, China), (R)-(-)-phenylephrine hydrochloride [Phe] (Sigma Aldrich, 
Germany), 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one [ODQ] (Cayman Chemical, 
USA) 3,5-Dicaffeoylquinic acid (Chromadex, USA), 3,4-Dicaffeoylquinic acid 
(Chromadex, USA), 4,5-Dicaffeoylquinic acid (Chromadex, USA)4-aminopyridine [4-AP] 
(Alfa Aesar, Germany), atropine (Sigma Aldrich, China), barium chloride dehydrate 
[BaCl2] (AnalaR Normapur - VWR International, Belgium), calcium chloride dehydrate 
[CaCl2, 2H2O] (Scharlau chemie, Spain), calmidazolium chloride (Sigma Aldrich, USA), 
carbamylcholine chloride [carbachol, CCH] (Sigma Aldrich, USA), chlorogenic acid 
(Sigma Aldrich, China), D(+)-glucose anhydrous (Sigma Aldrich_Riedel-de Haen, 
Germany), Enalapril maleate [Renitec®20mg] (Afric-Phar, Morocco), glybenclamide ( 
Sigma Aldrich, USA), hydroxocobalamin hydrochloride (Fluka, USA), heparin sodium 
salt (Sigma Aldrich, united kingdom), indomethacin (Sigma Aldrich-Fluka, Italy), 
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magnesium sulfate [MgSO4] (Sigma Aldrich, Germany), Nω-Nitro-L-arginine methyl 
ester hydrochloride [L-NAME] (Sigma Aldrich, Switzerland), potassium di-hydrogen 
phosphate [KH2PO4] (Panreac, Spain), Rp-8-bromo-β-phenyl-1,N2-
ethenoguanosine3′,5′-cyclicmonophosphorothioate sodium salt [Rp-8-Br-PET-cGMP] 
(Sigma Aldrich, Germany), sodium chloride [NaCl] (Sigma Aldrich_Riedel-de Haen, 
Denmark), sodium hydrogen carbonate [NaHCO3] (Farco chemical, Puerto Rico], 
sodium nitroprusside [SNP] (Farco chemical, Puerto Rico), sodium pentobarbital (Ceva 
Santé Animale, France), potassium chloride [KCl] (Sigma Aldrich_Riedel-de Haen, 
Germany), tetraethyl ammonium chloride hydrate [TEA] (Sigma Aldrich, USA), 
thapsigargin (Sigma Aldrich, Israel). The solvents utilized were: acetonitrile (Merck, 
Germany),diethyl ether (Sigma Aldrich, Germany), dimethyl sulfoxide [DMSO] (Sigma 
Aldrich_Riedel-de Haen, Germany), trifluoroacetic acid [TFA] (Merck, Germany). All 
chemicals and solvents used were analytical grade. The stock solutions of ODQ, 
thapsigargin and Rp-8-Br-PET-cGMP were prepared in DMSO whereas indomethacin 
was prepared in 5% (w/v) sodium bicarbonate solution. All other drugs were dissolved 
in distilled water. 
2.4. High performance Liquid Chromatography analysis (HPLC/UV-VIS-DAD) 
A sample of 10 mg/ml of AcAE was prepared in methanol and filtered through 
Chromafil® Pet -45/25 Macherey-Nagel (Germany) 0.45 µm filters. The analysis was 
carried out on an Agilent 1100 HPLC coupled with a DAD (Diode-Array Detector). A 
volume of 10 µl of the sample was injected on hypersil ODS column (5 µm, 250 × 4.6 
mm) and the analysis was operated at 25 ºC. The mobile phase was constituted of: TFA 
0.05 % in water (A), (pH=2.2) and acetonitrile (B). the sample was eluted at flow rate of 
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1 ml/min and with a linear gradient as follows: 100% (A) and 0% (B) at 0 min, 97% A 
and 3% (B) at 1 min, 60% A and 40% (B) at 45 min, 60% A and 40% (B) at 55 min, 40% A 
and 60% (B) at 56 min, 40% A and 60% (B) at 66 min and 100% (A) and 0% (B) at 67 
min. The obtained peaks were recorded using UV absorbance at 340 nm, and identified 
by comparing their retention time and UV spectra to those of standards from an 
internal database. The identified peaks were numbered 1 to 5 on the chromatogram 
(Fig. 1)  
Identification of peak 2  
The peak 2 was identified after carrying out a preparative HPLC (Varian). A 
concentration of 1g/10ml of AcAE was prepared in methanol, then, filtered through 
Acrodisc PSF GXF/GHP 0.45 nm filter. This solution was injected and eluted through 
Lichrospher 100 RP 18 column Merck® (250 x 25 mm, 12 µm), by using a mobile phase 
consisting of TFA 0.05% (A) and acetonitrile (B). A gradient elution was applied: 100% 
(A) at 0 min, 60% (A) at 30 min, 40% (A) at 40 min, 20% (A) at 45 min and 0% A at 55 
min. Flow rate was 30 ml/min. Detection was performed at 340 nm and time of collect 
is 0.20 min. The isolated peak (2) was re-analysed by LC/DAD, and identified by Mass 
Spectrometry and NMR. 
Mass spectra were set to negative ion mode. Experiments were performed with a 9.4 
tesla Apex-Qe FTICR mass spectrometer (Bruker Daltonics, Billerica, MA). NMR spectra 
were recorded in DMSO-d6 on a Bruker 500MHz NMR AVI spectrometer equipped with 
a cryoprobe operating at 500MHz for 1h and 125.7 MHz for 13C, with TMS as an 
internal reference 
2.5. Experimental animals 
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Wistar rats and albino mice were provided from the local colonies of department of 
Biology (Faculty of Sciences-Oujda, Morocco), they were maintained in standard 
conditions, with a photoperiod of 12 hours light and dark, at 24±2°C, and they were 
allowed to free access of water and food. All animals were cared for in compliance 
with the internationally accepted Guide for the care and use of laboratory animals, 
published by the US National Institutes of Health (NIH Publication No. 85-23, Revised 
in 1985). 
2.6. Acute toxicity test  
The acute toxicity of AcAE was carried out on mice of either sex weighing between 23 
and 43 g. Animals were divided into five groups of six mice each. The doses 1, 2, 4 and 
6 g/kg of AcAE were orally administered to the mice, while the control group was fed 
with tap water. The signs of toxicity or mortality were observed for the next 4 hours, 
then for the 48 hours and after the two weeks succeeding the administration of AcAE. 
2.7. Hypotensive effect on anesthetized rats 
Rats were anesthetized by an intraperitoneal injection of sodium pentobarbital (50 
mg/kg body weight) and kept at 37°C during the experiment. Catheters ﬁlled with 
heparin-saline solution (200 IU/ml) were inserted in the femoral vein for drug 
administration and in the femoral artery for arterial blood pressure recording by using 
a pressure transducer BP-T (EMKA Technologies, France). The systolic (SBP), diastolic 
(DBP), mean arterial pressure (MAP) and heart rate (HR) were visualized and analysed 
by using an acquisition card “National Instrument” and software Labview 6.1. The 
control values of MBP and HR were recorded just after 30 minutes of stabilisation. 
then, the baroreflex response of the animal was tested by assessing changes in MBP 
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and HR after an intravenous (i.v.) injection of bolus (25 µl/100 g of BW) of 
phenylephrine (PHE, 1.5 µg/kg) and sodium nitroprusside (SNP, 10 µg/kg). After 10 
minutes, the baseline values of MPB and HR were recorded, again, before (control) and 
after injection of AcAE (1, 2.5, 5, 10, 20, 30, 40 mg/kg). The injections were spaced by a 
time interval of 10 minutes, after stabilisation of the signal. 
2.8. Antihypertensive effect on L-NAME hypertensive rats.  
Male Wistar rats (N=39) weighing 180-320g were randomly divided into five groups; 
the control group received tap water (n=5), L-NAME group (n=6) received L-NAME (32 
mg/Kg/day), L-NAME + Enalapril (n=7) was co-treated with L-NAME 32 mg/Kg/day and 
Enalapril 15 mg/Kg/day, while, L-NAME + AcAE 50 (n=7) and L-NAME + AcAE 150 (n=7) 
received concomitantly L-NAME (32 mg/Kg/day) and respectively the doses 50 
mg/Kg/day and 150 mg/Kg/day of AcAE. All treatments were administered daily and 
orally at volume of 1ml/100g during 4 weeks. The SBP was indirectly measured at the 
beginning of the treatment and weekly throughout the treatment period, using the 
non-invasive tail cuff method. The rats were maintained on a holder restrained to get 
immobilised and placed at a heating table, kept approximately at 37°C for 15 minutes 
until they got stabilised and to ensure the blood flow on the caudal artery. The 
transducer placed around the tail and related to an inflation-deflation system 
permitted the detection of systolic blood pressure signal on plethysmograph apparatus 
(Innovators in Instrumentation, Landings, USA). 
2.9. Vasorelaxant effect on aorta isolated from normotensive rats 
Wistar rats weighing 200-300g were used. Rats were anesthetized with sodium 
pentobarbital (0.1ml/100g body weight). The thoracic aorta was quickly and gently 
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removed, cleaned of adherent connective tissue and cut into rings (3-4 mm in length). 
Rings were gently introduced between two stainless-steel hooks and placed in organ 
chamber (Emka technologies, France) containing 11 ml of Krebs solution gassed with 
95% O2 and 5% CO2 and maintained at 37 °C and pH 7.4. One hook was connected to 
an isometric force transducer (Emka technologies, France) and a tension of 1g was 
applied to the vessels then they were allowed to stabilize for 30 minutes. The 
composition of Krebs solution was as follow (mmol/L): NaCl 119, KCl 4.7, CaCl2 2.6, 
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and Glucose 11. Endothelial integrity was 
monitored by the percentage of relaxation evoked by carbachol (10-4 M) after a steady 
contraction was reached with phenylephrine (10-6 M). Rings with carbachol-induced 
relaxation less than 50% were discarded.  
2.9.1. Vasorelaxant effect of AcAE on intact and denuded precontracted aorta, and in 
the presence of Atropine and Calmidazolium 
In endothelium-intact aorta (n = 6), steady tension was evoked by phenylephrine 
(1 µM), then, AcAE (0.1–100 μg/ml) was cumulatively added to the Krebs solution. To 
verify if the relaxant effect of AcAE was mediated via the endothelium, denuded rings 
(n=6) were obtained by gentile rubbing of the lumen of aorta with a plier curved end, 
and the denudation was verified by the absence of any degree of relaxation caused by 
carbachol (10-4 M), then, AcAE (0.1–100 μg/ml) was cumulatively added. In another set 
of experiments, endothelium-intact rings were pre-incubated with the muscarinic 
receptor antagonist atropine (1 μM; n=6) and Ca2+-Calmodulin binding to NOS blocker 
calmidazolium chloride (10-3µM; n=6) for 20 minutes prior the contraction with 
phenylephrine (10-6M), then, the cumulative concentration–response curves of AcAE 
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were constructed and compared with those obtained with untreated rings. 
2.9.2. Vasorelaxant effect of AcAE in the presence of L-NAME, Hydroxycobalamin, 
ODQ and 8-RP-Br-PET-cGMP 
Endothelium-intact rings were pre-incubated with the NO synthase inhibitor, Nω-
Nitro-L-arginine methyl ester (L-NAME; 10-4 M; n = 6), the NO scavenger, 
hydroxocobalamin (3.10-5 M; n = 6), the guanylyl cyclase inhibitor, 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10-5M; n = 6), and the competitive 
cGMP-dependent protein kinase G (PKG) inhibitor, Rp-8-Br-PET-cGMP (3.10-6 M; n = 6) 
for 20 minutes prior the contraction with phenylephrine (10-6 M), then, the cumulative 
concentration–response curves of AcAE were constructed and compared with those 
obtained with untreated rings. 
2.9.3. Vasorelaxant effect of AcAE in the presence of potassium channels blockers, 
either TEA, or 4-AP, or BaCl2,or Glibenclamide 
Endothelium-intact rings were incubated with the Ca2+-activated potassium channels, 
tetraethyl ammonium (TEA; 10-2M; n=6), the selective voltage-activated potassium 
channel (Kv) blocker, 4-aminopyridine (4-AP; 10
-4M; n=6), the selective inwardly-
rectifying potassium channel blocker, barium chloride (BaCl2; 10
-4M; n=6), and the 
selective ATP-sensitive potassium channel blocker, glibenclamide (10-5M; n=6) for 20 
minutes prior to contraction with phenylephrine (10-6M); then, the cumulative 
concentration–response curves of AcAE were constructed and compared with those 
obtained with untreated rings. 
2.9.4. Vasorelaxant effect of AcAE in the presence of either Indomethacin,or 
Thapsigargin, or Verapamil 
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To determine if prostanoid (PGI2) was responsible of the relaxant effect of AcAE, 
endothelium-intact rings were pre-incubated with the non-selective cyclooxygenase 
inhibitor, indomethacin (10-5M; n=6), and to explore the role of calcium channels in the 
vasorelaxant effect, endothelium-intact rings were incubated with the Ca2+-channel 
type VOC, verapamil (10-5 M; n=6) and the endoplasmic reticulum Ca2+-ATPase (SERCA) 
inhibitor, thapsigargin (10-7 M; n=6) for 20 minutes prior to contraction with 
phenylephrine (10-6 M), then, the cumulative concentration–response curves of AcAE 
were constructed and compared to those obtained with untreated rings. 
2.10. Statistical analysis 
The data were expressed as the mean ± standard error of mean (SEM). The results 
were analysed using one-way and two-way analysis of variance (ANOVA), followed by 
Bonferroni’s as a post-test. A value of p < 0.05 was considered significant.  The 
chemical structures have been drawn by using the freeware version of the software 
ACD/ChemSketch (Freeware) 14.01.  
3. Results 
3.1. High performance liquid chromatography analysis (HPLC/UV-VIS-DAD) 
The HPLC analysis of AcAE reveals a quite simple chromatographic profile (see Fig. 1), 
with three major peaks: chlorogenic acid (peak 1), vicenin-2 (peak 2) and 3,5-
Dicaffeoylquinic acid (peak4). The peaks 1 to 5 were identified by means of their 
UV/vis spectra and their relative retention times, and literature data (Scifinder, 2016) 
corroborated these assignments. Co-injection with reference standards confirmed our 















Fig. 1. . LC chromatogram of A. campestris L. aqueous extract ( AcAE) visualized at the 
wave lenght of 340 nm. Peaks were detected using DAD detector. Peak (1): chlorogenic 
acid, peak (2): vicenin-2, peak (3): 3,4-dicaffeoylquinic acid (isochlogenic acid C), peak 
(4): 3,5-dicaffeoylquinic acid (isochlogenic acid A), peak (5): 4,5-dicaffeoylquinic acid 
(isochlogenic acid B). 
Vicenin-2 (apigenin 6, 8-di-C-glucoside) was identified by spectroscopic analysis 
(UV,MS and NMR) and comparison with literature data (Sawabe et al., 1989; Scifinder, 
2016). Chemical structures of identified compounds are represented in Fig. 2.  
3.2. Acute toxicity test 
The single oral dose of 1, 2, 4 and 6 g/Kg of AcAE administered to the mice did not 
produce any symptoms of toxicity or mortality during the 2 weeks observations. 
3.3. Hypotensive effect on anesthetized rats 
AcAE at doses 1, 2.5, 5, 10, 20, 30 and 40 mg/Kg reduced the systolic blood pressure 
(SBP) respectively, by 8.9±0.7, 8.1±2.4, 14.4±3.4, 21.3±2, 28.4±5.2, 32.5±2.7, 33.2±4 %, 
and the diastolic blood pressure (DBP) respectively, by 15.6±1.4, 8.4±2.5, 19.6±3.1, 




Fig. 2. Chemical structures of compounds identified in A. campestris L. aqueous extract 
(AcAE). 
 
Similarly, the mean arterial pressure (MAP) was lowered by treatment with AcAE; the 
reduction of MAP was:  7.6±1.3, 7.7±2.4, 20.2±4.6, 23.3±2.8, 32.1±6.3, 37.0 ±3.2, 
41.1±4.7 %, respectively at doses 1, 2.5, 5, 10, 20, 30 and 40 mg/Kg. Heart rate were 





Fig. 3. Effect of intravenous injection of A. campestris L.  (AcAE) on (A) systolic blood 
pressure (SBP) , (B) diastolic blood pressure (DBP), (C) mean arterial pressure (MAP) 
and (D) heart rat (HR) in anesthetized rats. Values are mean ± SEM, n=5. Two way 
ANOVA followed by Bonferroni’s post-test; * p < 0.05 and *** p <0.001 vs control 
(before treatment), NS: not significant. Original tracings showing the effect of 
intravenous injection of cumulative doses of A.campestris L. aqueous extract (AcAE) on 




3.4 Antihypertensive effect 
As shown in Fig. 4, at the beginning of the experiment, the baseline SBP values did not 
differ between the experimental groups. Daily administration of L-NAME (32 mg/Kg/j) 
induced a progressive increase in systolic blood pressure of L-NAME group from 
123.3±1.05 mmHg and reached 172.5±2.8 mmHg at the end of treatment. 
 
Fig. 4. Effect of four-weeks treatment on systolic bood pressure (SBP) of rats fed with 
L-NAME (L-NAME group), Enalapril (L-NAME+Enalapril group), and A.campestris L. 
aqueous extract at  50 mg/Kg/day (L-NAME+AcAE 50 group) and at 150 mg/Kg/day (L-
NAME+AcAE150 group). Data are mean ± S.E.M (n= 5-7 rats per group). Two way 
ANOVA followed by Bonferroni’s post-test; b: p < 0.01; c: p < 0.001 vs. control group; β: 
p < 0.01; γ: p < 0.001 vs. L-NAME group. 
 
This increase was significant from the first week until the end of experiment compared 
to control group (122.6 ± 1.9 mmHg; p < 0.001). At the end of the fourth week, the SBP 
of the rats in the L-NAME+Enalapril group (139.3 ± 2.5 mmHg; p < 0.001), L-NAME + 
19 
 
AcAE 50 group (146.4 ± 1.6 mmHg; p < 0.001) and L-NAME + AcAE 150 group (144.2 ± 
1.5 mmHg;  p < 0.001) was significantly lower than that of L-NAME group.  
3.5. Vasorelaxant effect on aorta isolated from normotensive rats 
3.5.1. Vasorelaxant effect of AcAE on intact and denuded precontracted aorta, and in 
the presence of Atropine and Calmidazolium 
AcAE (10-2 - 2 mg/ml) induced 95.8 ±1.8% (n=6) of relaxation of aorta contracted by 
phenylephrine (10-6 M). The vasorelaxation produced by AcAE was markedly 
attenuated after denudation of aorta (26.9% ±2.1; p<0.001). Also, the vasodilator 
effect was significantly reduced when aorta was pretreated with atropine, the 
muscarinic receptor inhibitor (69.9% ±7.1; p<0.001) and with calmidazolium, the 
calcium-calmodulin binding to NO synthase blocker (54.2% ±14.8; p<0.001) (Fig. 5). 
3.5.2. Vasorelaxant effect of AcAE in the presence of L-NAME, Hydroxycobalamin, 
ODQ and 8-RP-Br-PET-cGMP 
Vasorelaxant effect produced by AcAE (10-2 - 2 mg/ml) was decreased after the pre-
incubation of aorta with L-NAME, NO synthase inhibitor (35.1 ±5.1%; p<0.001), 
hydroxocobalamin, NO scavenger (38.9 ± 7.1%; p<0.001), ODQ, the guanylyl cyclase 
inhibitor (67.4 ±3.4%; p<0.001) and Rp-8-Br-PET-cGMP, the competitive cGMP-





Fig.5. (I) Concentration–response curves of the vasorelaxant effect of A.campestris L. 
aqueous extract (AcAE) on aorta isolated from normotensive rats and pre-contracted 
with phenylephrine 10-6 M (●), on denuded aorta (■), and in the presence of 
Atropine (▲) and Calmidazolium (▼).Values are mean ± SEM, n=5-6.Two way ANOVA 
followed by Bonferroni’s post-test; ** p<0.01 and *** p < 0.001 vs control.  (II) Original 
tracing showing the effect of charbachol 10-4 M on precontracte aorta with 
phenylephrine 10-6 M (endothelium integrity control) (A), and the vasorelaxant effect 
of A. campestris L. aqueous extract (AcAE) on isolated aorta pre-contracted with 
phenylephrine 10-6 M (B), on denuded aorta (C), and in the presence of atropine (D) 







Fig.6. (I) Concentration–response curves of the vasorelaxant effect of A.campestris L. 
aqueous extract (AcAE) on aorta isolated from normotensive rats and pre-contracted 
with phenylephrine 10-6 M (●), and in the presence of L-NAME (■), 
Hydroxocobalamin (▲), ODQ (▼) and 8-RP-Br-PET-cGMP (◆).Values are mean ± SEM, 
n=5-6.Two way ANOVA followed by Bonferroni’s post-test; * p < 0.05 and *** p < 0.001 
vs control. (II) Original tracing showing the effect of charbachol 10-4 M on precontracte 
aorta with phenylephrine 10-6 M (endothelium integrity control) (A), and the 
vasorelaxant effect of  A. campestris L. aqueous extract (AcAE) on isolated aorta pre-
contracted with phenylephrine 10-6 M (B), in the presence of  L-NAME (C), 




3.5.3. Vasorelaxant effect of AcAE in the presence of Indomethacin, Thapsigargin, 
Verapamil 
The vasorelaxant effect of AcAE (10-2 - 2 mg/ml) was inhibited after exposing aorta to 
the blocker of VOC-calcium channels, verapamil (36.2 ±3.3%; p<0.001) and to the 
inhibitor of endoplasmic reticulum calcium-ATPase, thapsigargin (30.7 ±3.8%; 
p<0.001). However, the inhibition of cyclooxygenase, by pretreatment with 
indomethacin did not alter the vasorelaxant effect evoked by AcAE (88.3 ±4.3%; 
p>0.05) (Fig. 7). 
3.5.4. Vasorelaxant effect of AcAE in the presence of potassium channels blockers, 
TEA, 4-AP, BaCl2 and Glibenclamide 
The relaxation triggered by AcAE (10-2-2 mg/ml) was not influenced after pretreatment 
of aorta with various potassium channels blockers such as  TEA (93.1 ±5.6%; p> 0.05), 
4-AP (90.8 ± 2.4%; p> 0.05), BaCl2 (87.7 ± 4.4%; p> 0.05) and glibenclamide (81.7 ± 
7.4%; p> 0.05) (Fig.8). 
4. Discussion 
The present work investigated the phytochemical composition of the aqueous extract 
of A. campestris L. (AcAE) from Oriental Morocco, and showed no acute toxicity when 
tested on mice. Moreover, the hypotensive effect of AcAE intravenous injection to 
normotensive rats and antihypertensive effect of oral administration of the extract to 
L-NAME induced hypertensive rats during four weeks have been highlighted; also, the 
vasorelaxant effect mechanism of action was explored on isolated rat aorta and 
pointed out that AcAE act through both endothelium dependent and independent 





Fig.7. (I) Concentration–response curves of the vasorelaxant effect of A.campestris L. 
aqueous extract (AcAE) on aorta isolated from normtensive rats andpre-contracted 
with phenylephrine 10-6 M (●) and in the presence of Thapsigargin (■), Verapamil 
(▲) and Indomethacin (▼). Values are mean ± SEM, n=6.Two way ANOVA followed by 
Bonferroni’s post-test; *** p < 0.001 vs control.(II) Original tracing showing the effect 
of charbachol 10-4 M on precontracte aorta with phenylephrine 10-6 M (endothelium 
integrity control) (A), and the vasorelaxant effect of  A. campestris L. aqueous extract 
(AcAE) on isolated aorta pre-contracted with phenylephrine 10-6 M (B), in the presence 




The HPLC analysis confirmed the presence of chlorogenic acid and three isochlorogenic 
acids: 3,4-dicaffeoylquinic acid (isochlorogenic acid B), 3,5-dicaffeoylquinic acid 
(isochlorogenic acid A) and 4,5-dicaffeoylquinic acid (isochlorogenic acid C). These 
findings are in congruence with a previous work carried out by Riedel et al. (2010), that 
found the same HPLC profile of cell culture of A. campestris L. occurring in Germany. 
Additional studies are available, showing the presence of chlorogenic acid in the 
phenolic-rich extract (Djeridane et al., 2007) and in the aqueous extract (Sebai et al., 
2014) of A. campestris L. 
The isochlorogenic acids were also detected in the water fraction and aqueous extract 
of A. campestris L. from Tunisia (Megdiche-Ksouri et al., 2015; Sebai et al., 2014). Data 
of other authors reported the occurrence of flavonoids such as chrysin, apigenin, 
luteolin, kaempferol, quercetin, myricetin and their derivatives (Akkari et al., 2014; De 
Pascual Teresa et al., 1986; De Pascual Teresa et al., 1984; Ferchichi et al., 2006; 
Hurabielle et al., 1982; Karabegović et al., 2011; Megdiche-Ksouri et al., 2015; Rauter 
et al., 1989; Sebai et al., 2014; Valant-Vetschera et al., 2003; Vasconcelos et al., 1998). 
Nevertheless, our study represents the first evidence about the existence of the 
glycoside flavonoid vicenin 2 as the main flavonoid present in the aqueous extract of A. 
campestris L. (AcAE) from Eastern Morocco.  
In a preliminary step to ensure the safety of AcAE, the extract was tested for it oral 
acute toxicity. Consequently, the LD50 was greater than 6 g/Kg, which seems to be 
much higher than that of the aqueous extract of Tunisian A.campestris L. orally 
administered to the mice (LD50 > 3.2 g/Kg) (Sebai et al., 2014), and injected 




Fig.8. (I) Concentration–response curves of the vasorelaxant effect of A.campestris L. 
aqueous extract (AcAE) on aorta isolated from normotensive rats andpre-contracted 
with phenylephrine 10-6 M (●), and in the presence of TEA (■), 4-AP (▲), BaCl2 (▼) 
and Glibenclamide (◆).Values are mean ± SEM, n=6. (II) Original tracing showing the 
effect of charbachol 10-4 M on precontracte aorta with phenylephrine 10-6 M 
(endothelium integrity control) (A), and the vasorelaxant effect of A. campestris L. 
aqueous extract (AcAE) on isolated aorta pre-contracted with phenylephrine 10-6 M 




The extract also revealed a positive safety profile explained by the absence of any 
behavioural perturbations during the 2 weeks following the administration. 
In our experiment, we proved the potential activity of A. campestris L. at lowering the 
blood pressure levels by testing the effect of AcAE on normotensive and hypertensive 
rats. Accordingly, the extract induced 41.1% drop of MAP of normal rats (with, 33.2% 
for SBP and 46.9% for DBP), at the dose of 40 mg/Kg, while the heart rate was not 
affected. The absence of any effect on the heart rate may lead to speculate that the 
hypotensive effect of AcAE is mainly mediated via a vascular pathway. 
Besides, an antihypertensive action on L-NAME induced hypertensive rats was 
evidenced, and the results showed that AcAE at doses 50 and 150 mg/Kg/day given 
concomitantly to the NO synthase inhibitor (L-NAME) exerted about the same degree 
of preventive action against the rise of SBP and which was comparable to the effect of 
reference antihypertensive drug (enalapril; angiotensin-converting enzyme (ACE) 
inhibitor). These data may suggest that the antihypertensive effect of AcAE is probably 
attributed to its ability to inhibit the impairment of NO signalling associated to L-NAME 
treatment (Paulis et al., 2008). In the light of these findings, it is noteworthy to point 
out that it has been shown in a previous study that aqueous extract of A. campestris 
leaves, prevents the induced hypertensive phase induced by the scorpion venom in 
rats, probably through adrenergic pathway (Ben Nasr et al., 2014b). 
The antihypertensive mechanism of action of AcAE was explored on vascular signalling 
pathways. Indeed, AcAE provoked a total relaxation of contracted aorta isolated from 
normotensive rats, which seems to be endothelium dependent, since the relaxant 
effect disappeared after the denudation process. Given the major importance of 
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endothelium in the regulation of vascular tone by releasing vasodilator factors such as 
nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived hyperpolarizing factor 
(EDHF) (Sandoo et al., 2010), the participation of endothelium mediators in the 
obtained vasorelaxant response was investigated. It is well known that the muscarinic 
vasorelaxation is mainly mediated via NO production in endothelial cells, which is 
triggered by the activation of endothelial nitric oxide synthase (eNOS), induced by 
Ca2+-calmodulin complex (Furchgott and Zawadzki, 1980; Harvey, 2012). Our results 
showed that the pre-treatment of aorta with atropine, a selective muscarinic receptor 
antagonist, and with calmidazolium, a Ca2+-calmodulin binding to NOS blocker, 
significantly reduced AcAE-induced vasorelaxation, which may suggest that the 
aqueous extract act via muscarinic receptor and interfere with the site of action of 
Ca2+-calmodulin complex in the vascular endothelium. More interestingly, NO was 
identified as the pilot modulator of vascular tone; once synthetized within the cytosol 
of endothelial cell by NOS, NO diffuses into adjacent vascular smooth muscle cells 
(VSMC) and bind to soluble guanylyl cyclase (sGC) which mediate the vasorelaxation 
action (Walford and Loscalzo, 2003). In this concern, we performed separate 
experiments, in which we preincubated aorta with L-NAME (NOS inhibitor) and with 
hydroxycobalamin (NO scavenger). In the presence of both blockers, AcAE induced-
vasorelaxation seems to be totally blunted, indicating the involvement of NO in the 
observed effect.  
The cyclic GMP-PKG signalling within the VSMC represents the final cascade of 
vasorelaxation initiated by NO production (Furchgott, 1983). Hence, it was reported 
that NO activates sGC that enhances the conversion of GTP to cGMP. Subsequently, 
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cGMP activates PKG that decreases the cytosolic free calcium level through several 
mechanisms, which finally resulted in the vessel relaxation (Hofmann et al., 2000). This 
asseveration was proved when vascular relaxation was lost on aorta submitted to 
ODQ, the inhibitor of sGC, and to Rp-8-Br-PET-cGMPs, the inhibitor of PKG; thing that 
may lead to postulate about the contribution of sGC and PKG in the vasodilatory effect 
of AcAE.  
The cyclooxygenase (COX) product, prostacyclin (PGI2), is an endogenous mediator of 
endothelium derived relaxation (Félétou et al., 2011), via activation of cAMP 
(Parkington et al., 2004). Nevertheless, the participation of prostacyclin in the 
vasorelaxant effect of AcAE was ruled out, because the relaxation was not affected by 
the treatment with the COX inhibitor, indomethacin. 
The intracellular calcium concentration [Ca2+]i is an ubiquitous parameter that 
regulates vascular smooth muscle contractile state. The major [Ca2+]i, is principally 
linked to the opening of voltage operated calcium (VOC) channels, which are finely 
controlled by the membrane potential (Ledoux et al., 2006). One the other hand, the 
re-uptake of intracellular calcium is considered as regulating mechanism of the 
vascular contractility, and the sarcoplasmic reticulum represents the major storage site 
of cytosolic calcium; in fact, the sequestration of excessive intracellular calcium occurs 
via an energy-dependent sarco-endoplasmic reticulum Ca2+-ATPase pump (SERCA) 
(Laporte et al., 2004). Our data reported significant decrease of vasoactivity of AcAE 
after the incubation with verapamil, the L-type calcium inhibitor, and thapsigargin 
(inhibitor of the SERCA pump), which indicates that SERCA activation and VOCC 
channels inhibition account for the vascular dilation produced by the extract. 
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Otherwise, the opening of potassium channels (K+) triggers an increase in K+ efflux, 
provoking membrane potential (Em) hyperpolarization and subsequent closure of VOC 
calcium channels, causing a decrease of intracellular Ca2+ mobilisation followed by a 
vasodilation (Ko et al., 2008; Sobey, 2001). Our findings reveal that pretreatment of 
aorta with potassium channels blockers did not modify the vascular effect of AcAE, 
which discarded the possible intervention of potassium channels in the vasorelaxant 
effect. 
As mentioned above, A.campestris L. extract (AcAE) exhibited a relevant 
antihypertensive effect on L-NAME-induced hypertensive rats, where the NO synthesis 
is assumed to be inhibited. So, one may wonder how AcAE is acting on a model where 
NOS is completely inhibited by L-NAME whereas its action is mediated mainly through 
the NO pathway. This effect, controversial and confusing at the first glimpse, can be 
well justified taking into account that the present treatment is aimed at exploring the 
preventive antihypertensive effect of AcAE rather than its curative effect, because the 
extract was administered concomitantly with L-NAME (the selective inhibitor of NOS), 
and so, the supplementation of AcAE for four weeks tended likely to prevent the 
presumable action of L-NAME to inhibit NO release by blockade of NOS and to avoid 
the development of hypertension. It is probable that the co-administration of L-NAME 
and the extract triggered a competitive action between the two products on NOS 
activity. Hence, the activator effect of AcAE on NOS seems to be more pronounced and 
succeeded to reduce the inhibitory effect of L-NAME, and so neutralizing the blockade 
of NOS. This hypothesis may lead to postulate that the treatment with AcAE is most 
efficient to prevent, with an earlier way, the NO deficiency, by acting on the vascular 
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compartment to increase the NO bioavailability leading to the vasorelaxant effect on 
the favor of the antihypertensive action.With respect to the human projected dose or 
human equivalent dose (HED), it was calculated according to the method proposed by 
Reagan-Shaw et al. (2008) and based on comparison of the body surface area of the 
different animal species. The HED for the aqueous extract of A. campestris L. (AcAE) 
are 8.1 mg/kg (486.5 mg for a 60 kg person) for the first dose of 50 mg/kg in the rat 
and 24.3 mg/kg (1.46 g of AcAE for a 60 kg person) for the second dose of 150 mg/kg in 
rats. Since the antihypertensive effect of the aqueous extract of A. campestris L. (AcAE) 
at the dose of 50 mg/kg was comparable to that of the standard drug (Enalapril) and 
taking into account the extraction yield (8.7%), the effective dose to be consumed by 
humans corresponds to 93.1 mg of the plant /kg of weight /day. For an adult person of 
60 kg, the daily necessary quantity is 5.59 g. Compared to infusion bags (which contain 
about 2 g of plant for one cup of water), this amount corresponds to 3 cups of herbal 
tea per day. Based on information from three herbalists interviewed in Oujda market, 
the recommended dose for the traditional use of A. campestris was estimated in a 
handful of the aerial part (approximately 20 g) in a cup (about 100 ml) of boiled water. 
The preparation can be consumed three times a day. Using the yield of the extraction 
found in our study (8.7%), the dose taken would be about 1.74 g of plant / 100 ml for 
each cup, which is the equivalent of 5.22 g of the net weight of the plant distributed 
three times a day. 
On the basis of these data, it can be concluded that the human dose projected (8.1 
mg/kg in humans, equivalent to 50 mg/kg in rats) is quite similar to the dose 
commonly used in traditional medicine. 
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Taking into account the antihypertensive effects of chlorogenic acids and mechanisms 
of improving endothelial function in hypertensive rats (Suzuki et al., 2006; Zhao et al., 
2012), and considering the abundance of AcAE on chlorogenic and isochlorogenic acids 
it can be hypothesized that such compounds are at least partially or even mainly 
responsible of the antihypertensive and vasorelaxant observed effects. Nevertheless, 
the effect of vicenin-2 (6,8-di-C-glucosylapigenin) could also play an important role in 
the effect of AcAE. Indeed, this flavonoid exhibited the strongest hypotensive activity 
for hypertensive rats among seventy-three glycosides investigated. This activity was 
not only found with intravenous administration (Sawabe et al., 1989), but also after 
oral administration. In the latter case, C-glucosyl flavonoids are considered to be not 
hydrolyzed by the digestive system and hydrochloric acid (Sawabe and Matsubara, 
1999). This hypothesis was recently confirmed by the investigations carried on vicenin-
2, the active principle of an anti-inflammatory Brazilian medicinal plant (Buqui et al., 
2015). Furthermore, vicenin-2 is a constituent of Crataegus monogyna, an old 
hypotensive medicinal plant used in Europe (Nikolov et al., 1981). 
5. Conclusion 
The present study gives evidence that A. campestris L. aqueous extract (AcAE) possess 
potent hypotensive, antihypertensive and vasorelaxant effects. The vasorelaxant effect 
of AcAE seems to be due to activation of muscarinic receptor and stimulating 
calmodulin-NO-sGC-PK pathway. An additional mechanism of action of AcAE is 
mediated via activation of SERCA pump and inhibition of VOCC channels. In relation 
with the chemical composition of AcAE it appears that the extract is predominantly 
composed of phenolic compounds (chlorogenic and isochlorogenic acids as well as 
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vicenin-2) which may be principally involved in the vasodilator effect.  
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